The lung cancer institute will work with Inivata to study the use of ctDNA testing in patients with early lung cancer after surgery.
Gencurix's assay can be used to select which non-small cell lung cancer patients will respond to tyrosine kinase inhibitors.
The PHG Foundation's report calls for raising clinician awareness about ctDNA testing technology in order to improve patient access to targeted therapies.
The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.
The company shared validation data this week that it said led the FDA to approve use of the test in a new prospective trial of Roche's Tecentriq in NSCLC.
Researchers from France's Gustave Roussy Institute designed EGFR mutation assays for the system, which they showed could be useful for testing in non-small cell lung cancer patients.
Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
The SPRING trial is exploring a three-drug strategy, starting with Ibrance, Inlyta, and Bavencio, and will validate a biomarker algorithm for predicting responders.
The initial FDA approval of Thermo Fisher's NGS panel test for personalizing cancer treatment may allow rapid expansion to new indications.
The New York City Police Department will be removing DNA profiles from a local database if they are from people who were never convicted of a crime, the New York Times reports.
Science reports that accusations of sexual assault against a microbiome researcher has also led to questions about his academic certifications.
Wired reports that researchers are analyzing the DNA fish leave behind in water to study their populations.
In Science this week: comprehensive cellular map of the human thymus, evidence of admixture between the ancestors of Neanderthals and Denisovan and a 'superarchaic' population.